Immune status for monitoring and treatment of bladder cancer

The high recurrence rate of non-muscle invasive bladder cancer (BC) and poor prognosis of advanced BC are therapeutic challenges that need to be solved. Bacillus Calmette-Guerin (BCG) perfusion was the pioneer immunotherapy for early BC, and the discovery of immune checkpoint inhibitors has created...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Shen, Li, Shijie, Zhan, Yunhong, Chen, Xiaonan, Sun, Ming, Liu, Xuefeng, Wu, Bin, Li, Zhenhua, Liu, Bitian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492838/
https://www.ncbi.nlm.nih.gov/pubmed/36159866
http://dx.doi.org/10.3389/fimmu.2022.963877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492838/
https://www.ncbi.nlm.nih.gov/pubmed/36159866
http://dx.doi.org/10.3389/fimmu.2022.963877

Ejemplares similares